NICE has recommended zanidatamab, also known as Ziihera and made by Jazz Pharmaceuticals, in final draft guidance for adults with HER2-positive advanced biliary tract cancer - a group of cancers ...
NICE has recommended a new take‑at‑home tablet for some people with chronic lymphocytic leukaemia whose disease has returned after treatment. The draft guidance could give patients greater choice and ...
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of ...
NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the ...
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) TA1144 8 April 2026 8 April 2026 Digital technologies ...
There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...
Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results